239 related articles for article (PubMed ID: 10587476)
1. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
Pulm Pharmacol Ther; 1999; 12(6):353-62. PubMed ID: 10587476
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bronchodilator responses of levosalbutamol and salbutamol given via a pressurized metered dose inhaler: a randomized, double blind, single-dose, crossover study.
Jantikar A; Brashier B; Maganji M; Raghupathy A; Mahadik P; Gokhale P; Gogtay J; Salvi S
Respir Med; 2007 Apr; 101(4):845-9. PubMed ID: 17276051
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.
Lötvall J; Palmqvist M; Arvidsson P; Maloney A; Ventresca GP; Ward J
J Allergy Clin Immunol; 2001 Nov; 108(5):726-31. PubMed ID: 11692096
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers.
Lipworth BJ; Clark DJ; Koch P; Arbeeny C
Thorax; 1997 Oct; 52(10):849-52. PubMed ID: 9404370
[TBL] [Abstract][Full Text] [Related]
6. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.
Lavorini F; Geri P; Luperini M; Maluccio NM; Mariani L; Marmai C; Pistolesi M; Fontana GA
Br J Clin Pharmacol; 2004 Nov; 58(5):512-20. PubMed ID: 15521899
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
[TBL] [Abstract][Full Text] [Related]
8. Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes.
van Baak MA; de Hon OM; Hartgens F; Kuipers H
Int J Sports Med; 2004 Oct; 25(7):533-8. PubMed ID: 15459835
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
Brookman LJ; Knowles LJ; Barbier M; Elharrar B; Fuhr R; Pascoe S
Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
[TBL] [Abstract][Full Text] [Related]
10. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
Lötvall J; Ankerst J
Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
[TBL] [Abstract][Full Text] [Related]
11. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
Kempsford R; Norris V; Siederer S
Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the bronchodilating efficacies of a novel salbutamol metered dose powder inhaler and a pressurised metered dose aerosol with a spacer.
Seppälä OP; Kari E; Elo J; Löyttyniemi E; Kunkel G
Arzneimittelforschung; 1998 Sep; 48(9):919-23. PubMed ID: 9793619
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the dose response to levalbuterol with and without pretreatment with S-albuterol after methacholine-induced bronchoconstriction.
Raissy HH; Harkins M; Esparham A; Kelly HW
Pharmacotherapy; 2007 Sep; 27(9):1231-6. PubMed ID: 17723076
[TBL] [Abstract][Full Text] [Related]
14. Agreement between two methods for assessing bioequivalence of inhaled salbutamol.
Lavorini F; Geri P; Camiciottoli G; Pistolesi M; Fontana GA
Pulm Pharmacol Ther; 2008; 21(2):380-4. PubMed ID: 17997115
[TBL] [Abstract][Full Text] [Related]
15. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma.
Ramsay CM; Cowan J; Flannery E; McLachlan C; Taylor DR
Eur J Clin Pharmacol; 1999 Jul; 55(5):353-9. PubMed ID: 10456484
[TBL] [Abstract][Full Text] [Related]
16. Equivalence of pharmacokinetic characteristics and bronchodilating effect between two combined formulations of nedocromil sodium and salbutamol: MDI and nebulizer solution.
Reggio S; Bustacchini S; Pistelli R; Valente S
Int J Clin Pharmacol Res; 1996; 16(1):19-27. PubMed ID: 9001926
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.
Gawchik SM; Saccar CL; Noonan M; Reasner DS; DeGraw SS
J Allergy Clin Immunol; 1999 Apr; 103(4):615-21. PubMed ID: 10200010
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans.
Boulton DW; Fawcett JP
Clin Pharmacol Ther; 1997 Aug; 62(2):138-44. PubMed ID: 9284849
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma.
Maier G; Rubino C; Hsu R; Grasela T; Baumgartner RA
Pulm Pharmacol Ther; 2007; 20(5):534-42. PubMed ID: 16891136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
